Real-time Diagnosis of Serum LECT 2 in Patient With Liver Cancer Using Electronic Antibody Sensor (e- Ab Sensor)
Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Jul 5, 2011
Trial Information
Current as of May 08, 2025
Unknown status
Keywords
ClinConnect Summary
Hepatocellular carcinoma (HCC) is one of the most common types of cancer in the world. High cancer recurrence is still the major cause of death of HCC patients. The major poor prognostic factors included vascular invasion, high α-FP, large tumor size, or tumor satellitosis, etc. Among the various literature reports with multivariate analysis, vascular invasion of the tumor is the major contribution of high recurrence and poor survival. Therefore, identifying differentially expressed genes between vascular-invasion and non-vascular invasion of HCCs is important.
After suppression subtractiv...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patients with liver cancer.
- • The patients without liver cancer.
- Exclusion Criteria:
- • 1. Inmates, aboriginal peoples, pregnant women, mental patients, students, subordinates and other vulnerable groups.
- • 2. Patients with malignant tumors.
- • 3. Patients will be excluded if they couldn't sign the consent.
About National Taiwan University Hospital
National Taiwan University Hospital (NTUH) is a leading medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a pioneer in medical education and patient care in Taiwan, NTUH integrates cutting-edge technology with comprehensive clinical expertise to facilitate groundbreaking studies across various medical fields. The hospital’s dedicated research team collaborates with local and international partners to enhance the understanding of diseases and improve treatment outcomes. By prioritizing patient safety and ethical standards, NTUH strives to contribute to the global medical community and foster advancements in healthcare practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei, , Taiwan
Patients applied
Trial Officials
Ming-Chih Ho, MD,PhD
Principal Investigator
National Taiwan University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials